Lack of an association between angiotensin receptor blocker based therapy and increased risk of cancer: Evidence from large observational studies

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Yang, Yuan ^a   Zhang, Fan ^b   Skrip, Laura ^c   Lei, Han ^a   Luo, Suxin ^a   Lu, Kai ^a   Hu, Dayi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; ETHNICITY; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; LUNG CANCER; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; COMPLICATION; META ANALYSIS; NEOPLASMS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; COHORT STUDIES; HUMANS; HYPERTENSION; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84925424707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119775     Document Type: Article

References (46)

1. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11: 627-36. doi: 10.1016/S1470-2045(10)70106-6 PMID: 20542468
2. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 12: 65-82. doi: 10.1016/S1470-2045(10)70260-6 PMID: 21123111
3. Matsuyama M, Funao K, Kuratsukuri K, Tanaka T, Kawahito Y, Sano H, et al (2010) Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp Ther Med 1(2): 301-6. PMID: 22993542
4. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-14. PMID: 9568680
5. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, et al (2005) Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 115(9): 2508-16. PMID: 16138193
6. Wasylyk B, Hahn SL, Giovane A (1993) The Ets family of transcription factors. Eur J Biochem 211(1-2): 7-18.
7. Page EL, Robitaille GA, Pouyssegur J, Richard DE (2002) Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 277(50): 48403-09. PMID: 12379645
8. Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Hasegawa M, Mikami S, et al (2010) Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Prostate 70(2): 162-9. doi: 10.1002/pros.21049 PMID: 19760626
9. Kinoshita J, Fushida S, Harada S, Yagi Y, Fujita H, Kinami S, et al (2009) Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int J Oncol 34(6): 1573-82. PMID: 19424575
10. Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16: 293-9. PMID: 16061390
11. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M (2005) Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26(2): 271-9. PMID: 15637093
12. ARB Trialists Collaboration (2011) Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 29(4): 623-35. doi: 10.1097/HJH.0b013e328344a7de PMID: 21358417
13. Batra VK, Gopalakrishnan V, McNeill JR, Hickie RA (1994) Angiotensin II elevates cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors. Cancer Lett 76(1): 19-24. PMID: 8124662
14. Gallagher PE, Tallant EA (2004) Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 25(11): 2045-52 PMID: 15284177
15. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L (2012) Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 344: e2697. doi: 10.1136/bmj.e2697 PMID: 22531797
16. Rao GA, Mann JR, Shoaibi A, Pai SG, Bottai M, Sutton SS, et al (2013) Angiotensin receptor blockers: are they related to lung cancer? J Hypertens 31(8):1669-75. doi: 10.1097/HJH.0b013e3283621ea3 PMID: 23822929
17. Rao GA, Mann JR, Bottai M, Uemura H, Burch JB, Bennett CL, et al (2013) Angiotensin receptor blockers and risk of prostate cancer among United States veterans. J Clin Pharmacol 53(7): 773-8. doi: 10.1002/jcph.98 PMID: 23686462
18. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen TJ, et al (2013) Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis. Int J Cardiol 167(5): 2162-6. doi: 10.1016/j.ijcard.2012.05.096 PMID: 22709730
19. Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S (2012) Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One 7(12): e50893. doi: 10.1371/journal.pone.0050893 PMID: 23251399
20. Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L (2012) Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol 74(1): 180-8. doi: 10.1111/j.1365-2125.2012.04170.x PMID: 22243442
21. Chang CH, Lin JW, Wu LC, Lai MS (2011) Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 29(22): 3001-7. doi: 10.1200/JCO.2011.35.1908 PMID: 21690476
22. Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A (2011) Use of angiotensin receptor blockers and the risk of cancer. Circulation 123(16): 1729-36. doi: 10.1161/CIRCULATIONAHA.110.007336 PMID: 21482967
23. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, et al (2011) Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 107(7): 1028-33. doi: 10.1016/j.amjcard.2010.11.026 PMID: 21256465
24. Koomen ER, Herings RM, Guchelaar HJ, Nijsten T (2009) Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cancer Epidemiol 33(5): 391-5. doi: 10.1016/j.canep.2009.10.005 PMID: 19896919
25. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7): e1000097. doi: 10.1371/journal.pmed.1000097 PMID: 19621072
26. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: URL: http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm [cited August 30, 2013].
27. Hamling J, Lee P, Weitkunat R, Ambuhl M (2008) Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Statist Med 27: 954-70.
28. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-58. PMID: 12111919
29. Overton Randall C (1998) A comparison of fixed-effects and mixed (random-effects) models for meta-analysis tests of moderator variable effects. Psychol Methods 3(3): 354-79.
30. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-34. PMID: 9310563
31. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-101. PMID: 7786990
32. Nakai Y, Isayama H, Ijichi H, Sasaki T, Takahara N, Ito Y, et al (2013) A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs 31(5): 1294-9. doi: 10.1007/s10637-013-9972-5 PMID: 23690239
33. Nakai Y, Isayama H, Ijichi H, Sasaki T, Kogure H, Yagioka H, et al (2012) Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci 103(8): 1489-92. doi: 10.1111/j.1349-7006.2012.02311.x PMID: 22515232
34. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al (2010) Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103(11):1644-8. doi: 10.1038/sj.bjc.6605955 PMID: 20978506
35. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135(10): 1429-35. doi: 10.1007/s00432-009-0587-3 PMID: 19399518
36. Sørensen GV, Ganz PA, Cole SW, Pedersen LA, Sørensen HT, Cronin-Fenton DP, et al (2013) Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 31(18): 2265-72. doi: 10.1200/JCO.2012.43.9190 PMID: 23650417
37. Chin HJ, Oh SW, Goo HS, Oh J, Noh JW, Cho JT, et al (2011) Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J Korean Med Sci 26(1): 59-66. doi: 10.3346/jkms.2011.26.1.59 PMID: 21218031
38. Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Shin SW, et al (2012) How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?. Oncology 83(6): 354-60. doi: 10.1159/000337979 PMID: 23052034
39. Yuge K, Miyajima A, Tanaka N, Shirotake S, Kosaka T, Kikuchi E, et al (2012) Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol 19(12): 3987-93. doi: 10.1245/s10434-012-2568-z PMID: 22872290
40. Makar GA, Holmes JH, Yang YX (2014) Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst 106(2): djt374.
41. Chiang YY, Chen KB, Tsai TH, Tsai WC (2014) Lowered cancer risk with ace inhibitors/ARBs: a population-based cohort study. J Clin Hypertens (Greenwich) 16(1): 27-33. doi: 10.1111/jch.12228 PMID: 24304931
42. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM (2010) Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 56(20): 1644-50. doi: 10.1016/j.jacc.2010.07.023 PMID: 21050974
43. Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sonmez A, Saglam M, Celik T, et al (2010) Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 5(7): 1174-81. doi: 10.2215/CJN.01110210 PMID: 20430947
44. Sugiura R, Ogawa H, Oka T, Koyanagi R, Hagiwara N; HIJ-CREATE Investigators (2012) Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). Am J Cardiol 109(4): 576-80. doi: 10.1016/j.amjcard.2011.09.050 PMID: 22100194
45. Pickel L, Matsuzuka T, Doi C, Ayuzawa R, Maurya DK, Xie SX, et al (2010) Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther 9(4): 277-85. doi: 10.4161/cbt.9.4.10643 PMID: 20026904
46. Qian YR, Guo Y, Wan HY, Fan L, Feng Y, Ni L, et al (2013) Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. Oncol Rep 29(6): 2408-14. doi: 10.3892/or.2013.2370 PMID: 23545945